Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
124
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

127
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

152
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
152

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-Reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Journal of Crohn's & colitis·2026
Same author

Tryptophan pathway metabotypes associate with disease activity and immune-metabolic dysfunction in inflammatory bowel disease.

medRxiv : the preprint server for health sciences·2026
Same author

Improvement in Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease Treated with Risankizumab vs Ustekinumab in the Phase 3B SEQUENCE Study.

The American journal of gastroenterology·2026
Same author

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.

The American journal of gastroenterology·2026
Same author

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.

Inflammatory bowel diseases·2026

Related Experiment Video

Updated: Jun 20, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.4K

IBD Matchmaking: Rational Combination Therapy.

Robert Battat1, John T Chang2, Edward V Loftus3

  • 1Division of Gastroenterology, Centre Hospitalier de l'Université de Montreal, Montreal, Quebec, Canada.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|July 18, 2024
PubMed
Summary
This summary is machine-generated.

Combined advanced targeted therapies (CATT) offer new hope for inflammatory bowel disease (IBD) patients with refractory disease. This strategy aims to improve treatment efficacy and overcome loss of response to individual therapies.

Keywords:
BiologicsCombinationDualSimultaneous

More Related Videos

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.5K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.2K

Related Experiment Videos

Last Updated: Jun 20, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.4K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.5K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.2K

Area of Science:

  • Gastroenterology and Immunology
  • Inflammatory Bowel Disease (IBD) Research

Background:

  • Increasing prevalence of refractory Crohn's disease and ulcerative colitis necessitates novel treatment strategies.
  • Current treatment limitations include low efficacy rates and frequent loss of response to individual advanced therapies.

Purpose of the Study:

  • To review conceptual frameworks, current evidence, and future applications of combined advanced targeted therapies (CATT) in IBD.
  • To provide context by examining combined therapies in other disease areas.
  • To explore the potential of CATT to address unmet needs in IBD management.

Main Methods:

  • Literature review of observational data and early-phase randomized controlled trials on CATT in IBD.
  • Analysis of combined therapy approaches in other chronic diseases.
  • Discussion of existing, novel, and orthogonal mechanisms of action for CATT.

Main Results:

  • Knowledge on CATT in IBD is primarily based on limited observational data and early-phase trials.
  • Combined therapies are a common strategy in managing other complex diseases.
  • Treatment exposure and disease duration are key factors influencing response to therapy.

Conclusions:

  • Combined advanced targeted therapies (CATT) represent a promising strategy to enhance treatment efficacy and durability in IBD.
  • Further research and clinical trials are needed to establish the safety and effectiveness of CATT.
  • CATT may be positioned to benefit a broader spectrum of the IBD population.